Multiple drugs
- PDF / 170,505 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 92 Downloads / 134 Views
1 S
Multiple drugs Myelosuppression and digestive tract reaction: case report.
An 85-year-old man developed myelosuppression and digestive tract reaction during treatment with cyclophosphamide, doxorubicin liposomal, prednisone, rituximab and vindesine for non-Hodgkin’s diffuse large B-cell lymphoma [DLBCL; not all routes and dosages stated]. The man presented with sinus and nasal disorder in May 2018. He was hospitalised and diagnosed with non-Hodgkin’s DLBCL on 25 June 2018. Because of long term use of aminophenazone/phenacetin tablets, he was found to have developed renal insufficiency. His serum creatinine level was 143 µmol/L. A treatment was planned to administer thrombopoietin 15000IU after every chemotherapy cycle due his advanced age and renal insufficiency. On 02 July 2018, first cycle of chemotherapy including rituximab 600mg by pump on day 1, IV drip cyclophosphamide 600mg on day 2, IV drip vindesine 4mg on day 2, oral prednisone 60mg from day 2-7 was administered. After first cycle, he developed myelosuppression level 2 and digestive tract reaction level 0. The man continued the chemotherapy and on 24 July 2018, he received second cycle of chemotherapy including rituximab 600mg by pump on day 1, IV drip cyclophosphamide 600mg on day 2, IV drip vindesine 4mg on day 2, IV drip doxorubicin liposomal [doxorubicin hydrochloride liposome] 40mg on day 2 and prednisone 60mg with gradual reduction from day 3-6 and stopped. He again developed myelosuppression and digestive tract reaction (both level 0). On 14 August 2018, he received third cycle of the chemotherapy. On 10 September 2018, he received fourth cycle including only rituximab 600mg on day 1. On 09 October 2018, he received fifth cycle of the chemotherapy. As per the plan, he was treated with thrombopoietin after every chemotherapy cycle. On 15 October 2018, PET-CT scan revealed thickened left nasal mucosa, slightly elevated metabolism, right maxillary sinus and ethmoid sinusitis, elevated metabolism on the left side of nasopharynx with complete molecular score of 1-2. On 30 October 2018, he received sixth chemotherapy including only rituximab. After every cycle, he developed myelosuppression and digestive tract reaction [outcomes not stated]. He tolerated chemotherapy well and achieved complete remission following the chemotherapy. Ma C, et al. Non-Hodgkin’s lymphoma in an elderly patient with renal dysfunction: a case report. Journal of International Medical Research 48: No. 8, 13 Aug 2020. Available from: URL: http://doi.org/10.1177/0300060520945858
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803500660
Reactions 12 Sep 2020 No. 1821
Data Loading...
